Use of transgenic animals in regulatory carcinogenicity evaluations

Alternative Toxicological Methods

Volumn , Issue , 2003, Pages 391-412

  Sistare, Frank D ^a   Jacobs, Abigail C ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 1342300916     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (75)

1. Albert, R., French, J., Maronpot, R., Spalding, J., and Tennant, R. (1996) Mechanism of skin tumorigenesis by contact sensitizers: the effect of the corticosteroid fluocinolone acetonide on inflammation and tumor induction by 2,4-dinitro-1-fluorobenzene in the skin of the Tg.AC (v-Ha-ras) mouse, Environ. Health Perspect, 104, 1062-1068.
2. Bhat, H.K., Han, X., Gladek, A., and Liehr, J.G. (1994) Regulation of the formation of the major diethylstilbestrol-DNA adduct and some evidence of its structure, Carcinogenesis, 15, 2137-2142.
3. Blanchard, K.T., Barthel, C., French, J.E., Holden, H.E., Moretz, R., Pack, F.D., Tennant, R.W., and Stoll, R.E. (1999) Transponder-induced sarcoma in the heterozygous p53(+/-) mouse, Toxicol. Pathol., 27, 519-527.
4. Boley, S.E., Anderson, E.E., French, J.E., Donehower, L.A., Walker, D.B., and Recio, L. (2000) Loss of p53 in benzene-induced thymic lymphomas in p53+/- mice: evidence of chromosomal recombination, Cancer Res., 60, 2831-2835.
5. Boley, S.E., Wong, V.A., French, J.E., and Recio, L. (2002) p53 heterozygosity alters the mRNA expression of p53 target genes in the bone marrow in response to inhaled benzene, Toxicol. Sci., 66, 209-215.
6. Bolon, B. and Galbreath, E. (2002) Use of genetically engineered mice in drug discovery and development: wielding Occam’s razor to prune the product portfolio, Int. J. Toxicol., 21, 55-64.
7. Cannon, R.E., Spalding, J.W., Trempus, C.S., Szczesniak, C.J., Virgil, K.M., Humble, M.C., and Tennant, R.W. (1997) Kinetics of wound-induced v-Ha-ras transgene expression and papilloma development in transgenic Tg.AC mice, Mol. Carcinog., 20, 108-114.
8. Cavalieri, E., Frenkel, K., Liehr, J.G., Rogan, E., and Roy, D. (2000) Estrogens as endogenous genotoxic agents — DNA adducts and mutations, J. Natl. Cancer Inst. Monogr, pp. 75-93.
9. De Vries, A., van Oostrom, C.T.H., Hofhuis, F.M.A., Dortant, PM., Berg, R.J.W., De Gruijl, F.R., Wester, PW., Van Kreijl, C.F., Capel, PJ.A., Van Steeg, H., and Verbeek, S.J. (1995) Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA Nature, 377, 169-173.
10. De Vries, A., van Oostrom, C.T.H., Dortant, PM., Beems, R.B., Van Kreijl, C.F., Capel, PJ.A., and Van Steeg, H. (1997a) Spontaneous liver tumours and benzo[a]pyrene-induced lymphomas in XPA-deficient mice, Mol. Carcinog., 19, 46-53.
11. De Vries, A., Dolle, M.E., Broekhof, J.L., Muller, J.J., Kroese, E.D., van Kreijl, C.F., Capel, PJ., Vijg, J., and van Steeg, H. (1997b) Induction of DNA adducts and mutations in spleen, liver and lung of XPA-deficient/lac Z transgenic mice after oral treatment with benzo[a]pyrene: correlation with tumour development, Carcinogenesis, 18, 2327-2332.
12. Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery, C.A.J., Butel, J.S., and Bradley, A. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors, Nature, 356, 215-221.
13. Eastin, W.C., Mennear, J.H., Tennant, R.W., Stoll, R.E., Braustetter, D.G., Bucher, J.R., McCullough, B., Binder, R.L., Spalding, J.W., and Mahler, J.F. (2001) Tg.AC genetically altered mouse: assay working group overview of available data, Toxicol. Pathol., 29(Suppl.), 60-80.
14. Elmquist, W.F. and Miller, D.W. (2001) The use of transgenic mice in pharmacokinetic and pharmacodynamic studies, J. Pharm. Sci., 90, 422-435.
15. Fearon, E.R. and Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis, Cell, 61, 759-767.
16. French, J., Storer, R.D., and Donehower, L.A. (2001) The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens, Toxicol. Pathol., 29(Suppl.), 24-29.
17. Galloway, S.M., Johnson, T.E., Armstrong, M.J., and Ashby, J. (2000) The genetic toxicity of the peroxisome proliferator class of rodent hepatocarcinogen, Mutat. Res., 448, 153-158.
18. Gingrich, J.R., Barrios, R.J., Morton, R.A., Boyce, B.F., DeMayo, F.J., Finegold, M.J., Angel opoulou, R., Rosen, J.M., and Greenberg, N.M. (1996) Metastatic prostate cancer in a transgenic mouse, Cancer Res., 56, 4096-4102.
19. Gonzalez, FJ. (2002) The peroxisome proliferator-activated receptor alpha (PPARalpha): role in hepatocarcinogenesis, Mol. Cell Endocrinol., 193, 71-79.
20. Greenblatt, M.S., Bennett, W.P, Hollstein, M., and Harris, C.C. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis, Cancer Res., 54, 4855-4878.
21. Greten, F.R., Wagner, M., Weber, C.K., Zechner, U., Adler, G., and Schmid, R.M. (2001) TGF alpha transgenic mice. A model of pancreatic cancer development, Pancreatol-ogy, 1, 363-368.
22. Gulezian, D. (1999) Managing intellection property rights for improved access to transgenic technology, Lab. Animal, 28, 28-32.
23. Hamadeh, H.K., Bushel, PR., Jayadev, S., Martin, K., DiSorbo, O., Sieber, S., Bennett, L., Tennant, R., Stoll, R., Barrett, J.C., Blanchard, K., Paules, R.S., and Afshari, C.A. (2002) Gene expression analysis reveals chemical-specific profiles, Toxicol. Sci., 67, 219-231.
24. Hansen, L.A. and Tennant, R.W. (1994) Follicular origin of epidermal papillomas in v-Ha-ras transgenic Tg.AC mouse skin, Proc. Natl. Acad. Sci. U.S.A., 91, 7822-7826.
25. Harris, S., Davis, N.K., Jowett, M.I., Rees, E.S., and Topps, S. (1993) Transgenic animals as tools in drug development, Agents and Actions, 38, c57-c58.
26. Harvey, M., McArthur, M.J., Montgomery, C.A.J., Butel, J.S., Bradley, A., and Donehower, L.A. (1993) Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice, Nat. Genet., 5, 225-229.
27. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C.C. (1991) p53 mutations in human cancers, Science, 253, 49-53.
28. Honchel, R., Rosenzweig, B., Thompson, K.L., Blanchard, K.T., Furst, S.M., Stoll, R.E, and Sistare, F.D. (2001) Loss of palindromic symmetry in Tg.AC mice with a nonresponder phenotype, Mol. Carcinog., 30, 99-110.
29. Hulla, J.E., French, J.E, and Dunnick, J.K. (2001) Chromosome 11 loss from thymic lymphomas induced in heterozygous Trp53 mice by phenolphthalein, Toxicol. Sci., 60, 264-270.
30. International Conference on Harmonization, Expert Working Group on Safety (1997) Guidance for Industry SIB Testing for Carcinogenicity of Pharmaceuticals, www.fda.gov/cder/guidance/index.htm.
31. Jacks, T., Remington, L., Williams, B.O., Schmitt, E.M., Halachmi, S., Bronson, R.T., and Weinberg, R.A. (1994) Tumor spectrum analysis in p53-mutant mice, Curr. Biol., 4, 1-7.
32. Johnson, F.M. (1999) Carcinogenic chemical-response “fingerprint” for male F344 rats exposed to a series of 195 chemicals: implications for predicting carcinogens with transgenic models, Environ. Mol. Mutagenesis, 34, 234-245.
33. Kemp, C.J., Donehower, L.A., Bradley, A., and Balmain, A. (1993) Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors, Cell, 5, 813-822.
34. Kraemer, K.H., Lee, M.M., and Scotto, J. (1984) DNA repair protects against cutaneous and internal neoplasia: evidence from xeroderma pigmentosum, Carcinogenesis, 5, 511-514.
35. Lane, D.P (1992) Cancer: p53, guardian of the genome, Nature, 358, 15-16.
36. Leder, A., Kuo, A., Cardiff, R., Sinn, E., and Leder, P. (1990) v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid, Proc. Natl. Acad. Sci. U.S.A., 87, 9178-9182.
37. Leder, A., Lebel, M., Zhou, F., Fontaine, K., Bishop, A., and Leder, P (2002) Genetic interaction between the unstable v-Ha-RAS transgene (Tg.AC) and the murine Werner syndrome gene: transgene instability and tumorigenesis, Oncogene, 21, 6657-6668.
38. Livingston, J.N. (1999) Genetically engineered mice in drug development, J. Internal Med., 245, 627-635.
39. MacDonald, J.S., Lankas, G.R., and Morrissey, R.E. (1994) Toxicokinetic and mechanistic considerations in the interpretation of the rodent bioassay, Toxicol. Pathol., 22, 124-140.
40. Marshall, E. (2002) DuPont ups ante on use of Harvard’s Oncomouse, Science, 296, 1212-1213.
41. Maruyama, C., Tomisawa, M., Wakana, S., Yamazaki, H., Kijima, H., Suemizu, H., Ohnishi, Y., Urano, K., Hioki, K., Usui, T., Nakamura, M., Tsuchida, T., Mitsumori, K., Nomura, T., Tamaoki, N., and Ueyama, Y. (2001) Overexpression of human H-ras transgene is responsible for tumors induced by chemical carcinogens in mice, Oncol. Rep., 8, 233-237.
42. Megosh, L., Gilmour, S.K., Rosson, D., Soler, A.P., Blessing, M., Sawicki, J.A., and O’Brien, T.G. (1995) Increased frequency of spontaneous skin tumors in transgenic mice which overexpress ornithine decarboxylase, Cancer Res., 55, 4205-4209.
43. Merlino, G.T. (1991) Transgenic animals in biomedical research, FASEB J., 5, 2996-3001.
44. Morris, S.M. (2002) A role for p53 in the frequency and mechanism of mutation, Mutat. Res., 511, 45-62.
45. Morton, D., Alden, C.L., Roth, A.J., and Usui, T. (2002) The TgrasH2 mouse in cancer hazard identification, Toxicol. Pathol., 30, 75-79.
46. Moser, G.J., Trempus, C.S., Mahler, J.F., Ward, S.M., Wilson, R., M. Streicker, M., Tice, R.R., Goldsworthy, T.L., and Tennant, R.W. (2001) Topical exposure of v-Ha-ras Tg.AC mice to the insecticide rotenone, Toxicologist, 60, 278.
47. Nakane, H., Takeuchi, S., Yuba, S., Saijo, M., Nakatsu, Y., Murai, H., Nakatsuru, Y., Ishikawa, T., Hirota, S., Kitamura, Y., Kato, Y., Tsunoda, Y., Miyauchi, H., Horio, T., Tokunaga, T., Matsunaga, T., Nikaido, O., Nishimune, Y., Okada, Y., and Tanaka, K. (1995) High incidence of ultraviolet-B or chemical-carcinogen-induced skin tumors in mice lacking the xeroderma pigmentosum group A gene, Nature, 377, 165-168.
48. Nylander-French, L.A. and French, J.E. (1998) Tripropylene glycol diacrylate but not ethyl acrylate induces skin tumors in a twenty-week short-term tumorigenesis study in Tg.AC (v-Ha-ras) mice, Toxicol. Pathol., 26, 476-483.
49. Palmiter, R.D. and Brinster, R.L. (1986) Germ-line transformation of mice, Ann. Rev. Genet., 20, 465-499.
50. Peters, J.M., Cattley, R.C., and Gonzalez, FJ. (1997) Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643, Carcinogenesis, 18, 2029-2033.
51. Pritchard, J.B., French, J.E., Davis, B.J., and Haseman, J.K. (2002) Transgenic models: their role in carcinogen identification, Environ. Health Perspect., doi: 10.12.89/ehp.5778 (available at http://dx.doi.org).
52. /− and C57Bl6 mice, Toxicologist, 54, 222.
53. Robinson, D.E. and MacDonald, J.S. (2001) Background and framework for ILSI's collaborative evaluation program on alternative models for carcinogenicity assessment, Toxicol. Pathol., 29(Suppl.),13-19.
54. Salleh, M.N., Caldwell, J., and Carmichael, P.L. (2003) A comparison of gene expression changes in response to diethylstilbestrol treatment in wild-type and p53(+/-) hem-izygous knockout mice using focussed arrays, Toxicology, 185, 49-57.
55. Sands, A.T., Abuin, A., Sanchez, A., Conti, C.J., and Bradley, A. (1995) High susceptibility to ultraviolet-induced carcinogenesis in mice lacking XPC, Nature, 377, 162-165.
56. Serrano, M., Lee, H., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R.A. (1996) Role of the INK4a locus in tumor suppression and cell mortality, Cell, 85, 27-37.
57. 32P-postlabeling analysis of DNA adducts in rats during estrogen-induced hepatocarcinogenesis and effect of tamoxifen on DNA adduct level, Jpn. J. Cancer Res., 83, 438-444.
58. Sistare, F.D., Thompson, K.L., Honchel, R., and DeGeorge, J. (2002) Evaluation of the Tg.AC transgenic mouse assay for testing the human carcinogenic potential of pharmaceuticals — practical pointers, mechanistic clues, and new questions, Int. J. Toxicol., 21, 65-79.
59. Stoll, R.E., Furst, S.M., Stoltz, J.H., Lilly, P.D., and Mennear, J.H. (2001) Dermal carcinogenicity in transgenic mice: effect of vehicle on responsiveness of hemizygous Tg.AC mice to phorbol 12-myristate 13-acetate (TPA), Toxicol. Pathol., 29, 535-540.
60. /− hemizygous knockout mouse: overview of available data, Toxicol. Pathol., 29(Suppl.), 30-50.
61. Suemizu, H., Muguruma, K., Maruyama, C., Tomisawa, M., Kimura, M., Hioki, K., Shi-mozawa, N., Ohnishi, Y., Tamaoki, N., and Nomura, T. (2002) Transgene stability and features of rasH2 mice as an animal model for short-term carcinogenicity testing, Mol. Carcinog., 34, 1-9.
62. Swing, S. (2001) Intellectual property issues involving transgenic rodent models, Am. Genomic/Proteomic Technol., 1, 25-26.
63. Tamaoki, N. (2001) The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis, Toxicol. Pathol., 29(Suppl.), 81-89.
64. Tennant, R.W., Stasiewicz, S., Eastin, W.C., Mennear, J.H., and Spalding, J.W., (2001) The Tg.AC (v-Ha-ras) transgenic mouse: nature of the model, Toxicol. Pathol., 29(Suppl.), 51-59.
65. Thompson, K., Rosenzweig, B., and Sistare, F. (1998) An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness, Toxicol. Pathol., 26, 548-555.
66. Thompson, K.L., Rosenzweig, B.A., Honchel, R., Cannon, R.E., Blanchard, K.T., Stoll, R.E., and Sistare, F.D. (2001) Loss of critical palindromic transgene promoter sequence in chemically induced Tg.AC mouse skin papillomas expressing transgene-derived mRNA, Mol. Carcinog., 32, 176-186.
67. Usui, T., Mutai, M., Hisada, S., Takoaka, M., Soper, K.A., McCullough, B., and Alden, C. (2001) CB6F1-rasH2 mouse: overview of available data, Toxicol. Pathol., 29(Suppl.), 90-108.
68. Van Dyke, T. and Jacks, T. (2002) Cancer modeling in the modern era: progress and challenges, Cell, 108, 135-144.
69. /− knockout mice: overview of available data, Toxicol. Pathol., 29(Suppl.), 117-127.
70. Van Lohuizen, M., Verbeek, S., Krimpenfort, P, Domen, J., Saris, C., Radaszkiewiczs, T., and Berns, A. (1989) Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors, Cell, 56, 673-682.
71. Van Oostrom, C.T., Boeve, M., van Den Berg, J., de Vries, A., Dolle, M.E., Beems, R.B., van Kreijl, C.F., Vijg, J., and van Steeg, H. (1999) Effect of heterozygous loss of p53 on benzo[a]pyrene-induced mutations and tumors in DNA repair-deficient XPA mice, Environ. Mol. Mutagen., 34, 124-130.
72. Van Steeg, H. (2001) The role of nucleotide excision repair and loss of p53 in mutagenesis and carcinogenesis, Toxicol. Lett., 120, 209-19.
73. /− knock-out mice: nature of the models, Toxicol. Pathol., 29(Suppl.), 109-116.
74. Venkatachalam, S., Tyner, S.D., Pickering, C.R., Boley, S., Recio, L., French, J.E., and Donehower, L.A. (2001) Is p53 haplo insufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing, Toxicol. Pathol., 29(Suppl.), 147-154.
75. Ward, J.M., Peters, J.M., Perella, C.M., and Gonzalez, FJ. (1998) Receptor and nonreceptor-mediated organ-specific toxicity of di(2-ethylhexyl)phthalate (DEHP) in peroxisome proliferator-activated receptor alpha-null mice, Toxicol. Pathol., 26, 240-246.